Home | Publications | Company Information | Top 50 Pharma | Abbott Laboratories place holder
place holder place holder

Abbott Laboratories


Abbott Laboratories

Pipeline,Products,Performance,Potential

Publication Date   March 2008
Publisher   Espicom
Product Type   Strategic Report
Pages   142
ISBN Number   not applicable
Product Code   ESP1005
Ask a question about this product?

Price £595.00

approximately: $1,178 | €756

Summary


Pharmaceutical company intelligence reports from Espicom provide a full review of the company's activities together with five-year sales forecasts for its key products. The company's financial performance is covered in-depth, from its latest results to a complete analysis of its latest full fiscal year and an outlook for the future. A section on company strategy covers mergers, acquisitions and divestitures, key agreements, products and R&D. An overview of key products and R&D is followed by a comprehensive review of the company's product portfolio and research and development pipeline by therapeutic area. In addition, supplementary appendices provide more in-depth information on financials, agreements and corporate events.

Content


  • Executive Summary
    • A detailed and comprehensive overview of current financial position, company strategy, product and pipeline analysis.
  • Therapeutic Area Focus
    • Key product analysis and forecasting
    • Inflammation
      • Humira (adalimumab)
    • Cardiovascular
      • TriCor (fenofibrate)
    • Neuroscience
      • Depakote/Epival/Valcote (divalproex sodium)
    • Virology
      • Kaletra (lopinavir+ritonavir)
    • Anti-infectives
      • Biaxin/Klacid/Klaricid/Biclar (clarithromycin)
      • Omnicef (cefdinir)
    • Anaesthetics
      • Sevorane/Ultane (sevoflurane)
    • Metabolic
      • Synthroid (levothyroxine sodium)
    • Oncology
      • Lupron Depot/Lucrin (leuprolide)
    • Gastrointestinal
      • Prevacid (lansoprazole)
  • Operational Data
    • A wealth of background and detail
    • A full 5-year financial performance assessment
    • Key agreements
    • Infrastructure
    • Subsidiaries and joint ventures